A user beginning to take Pyrilutamide as a treatment for their hairloss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.
This conversation was about a user's progress pictures from using minoxidil and microneedling to treat hairloss. Other users suggested finasteride as an additional treatment, while cautioning that the drug could have permanent side effects.
The conversation discusses skepticism about the effectiveness of new hairloss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
User experienced side effects from topical finasteride, including penile pain and reduced sexual satisfaction, and is unsure whether to resume or avoid the treatment. They are seeking advice on whether tapering off the drug might help.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hairloss treatment. The user is not comfortable buying it as a research drug from China.
A female user's experience using Spironolactone to treat Female Pattern HairLoss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hairloss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.
The conversation provides scientific sources on hairloss treatments like finasteride, minoxidil, and others, aiming to help individuals make informed decisions about their treatment options. It also discusses phytochemicals as alternative treatments due to concerns about side effects from drug-based therapies.
The conversation discusses a user's positive experience with hair regrowth using topical finasteride, minoxidil, and microneedling after 2.5 months, noting initial shedding but improved hair density, especially at the temples, possibly eliminating the need for a hair transplant. The user is satisfied with the current treatment and is hesitant to try the experimental drug RU58841, hoping the current routine will suffice for further improvements.
The conversation is about the lack of improvement in hairloss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.
A Silicon Valley-backed company aims to cure hairloss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
Hairloss treatments discussed include Minoxidil, Finasteride, RU58841, ass hair transplant, topical Viagra, castration, and transitioning to female. A user mentions an experimental drug called M4U-5 (Mousteride) that turns you into a mouse.
The user checked iron, ferritin, B12, zinc, testosterone, DHT, and estrogens to understand hairloss causes and the effects of dutasteride. They also noted increased heart rate and paleness with oral minoxidil.
The user has been using RU58841, topical Minoxidil, Ketoconazole shampoo, and a Dermastamp for 8 months, and Finasteride for 7 months to treat hairloss. They apply RU58841 daily, use Minoxidil and Dermastamp regularly, take Finasteride daily, and have not experienced side effects.
First patient dosed with Pyrilutamide (Kintor) Phase III for hairloss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
The user successfully reduced hairloss using pumpkin seed oil, Nizoral shampoo, and astaxanthin without using minoxidil or finasteride. They observed significant improvement over 12 months and believe the combination of treatments is effective.
The user shared their positive experience with finasteride for hairloss over seven years, noting it stopped hair recession and maintained their hairline. They also mentioned using minoxidil irregularly and experiencing a lower sperm count but no erectile dysfunction.
Combining Minoxidil with Peppermint or Rosemary Oil may enhance hair growth. Users discuss the potential benefits of this combination for treating hairloss.
The post discusses a new hairloss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
RU58841 is being discussed for its effects on hairloss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.
The user has been using finasteride and minoxidil for hairloss for 2 years and started microneedling, now considering a hair transplant in Mexico. Suggestions include trying dutasteride, oral minoxidil, and various opinions on hair transplant locations and the user's current hair condition.